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We have been concerned for some time with an apparent progressive loss of clarity between acts 
of veterinary surgery and animal experimentation, particularly with respect to companion animals.  
Our concerns were heightened by a Nature editorial published on the 8th December 2016 entitled, 
“Pet projects need a helping hand” and subtitled, “Clinical trials with cats and dogs offer great 
promise for animal and human medicine but risk being stifled by overzealous regulations” (Anon 
2016).  This article proposed that the EU directive 2010/63 be relaxed so that veterinarians can 
conduct clinical trials on pet animals.   
 
In the recent editorial, it was suggested that ‘overzealous regulations’ are stifling scientific 
progress by limiting the use of companion animals in clinical trials of treatments of both human 
and animal disease. Whilst we accept the possibility of some benefit arising from such studies, we 
feel Nature significantly underestimates the potential for harms to be caused to the animals used. 
We argue that robust regulation is necessary for clinical trials carried out using companion 
animals, just as it is for all scientific uses of animals and for human clinical trials. Indeed, ethical 
oversight for trials on companion animals which involve the potentially competing interests of 
animals, owners, treating clinicians and trial funders may be in even more need of independent 
ethical review and oversight than most other forms of animal research. 
 
The editorial suggests that using pets for clinical trials is scientifically more valid because they are 
the “real McCoy”: they are genetically diverse, develop the disease spontaneously and share the 
human environment, and therefore reflect the real-life situation for people. This approach ignores 
many of the problems inherent in studying naturally occurring disease. Robust scientific evidence 
relies upon targeted research and the selection of an appropriate model. Clinical research has 
obvious value but because of the very considerable variation between individuals and their 
respective disease processes, large numbers of cases must be recruited. Many factors may 
influence disease onset and progression which may be hard to identify and quantify, not least 
because significant gaps in the medical history are common. Consequently, to produce reliable 
information, use of clinical cases often requires specialist experimental design and use of complex 
statistics.  There is, therefore, the very real possibility that clinical trials may fail to deliver 
meaningful outcomes. One of the fundamental purposes of regulation of the use of animals in 
experiments or clinical trials is the assessment of the likelihood and importance of a successful 
trial outcome, before the research begins. Where benefit is unlikely to be achieved or is of little 
clinical significance, the research should not be allowed to proceed. Thus, the regulatory system 
offers an important test of the quality of the research, which may be especially important for the 
very kind of research that the Nature editorial suggests should not undergo such regulation. 
 
Leaving aside arguments in relation to model validity, similar ethical concerns apply to subjects 
of research procedures, be they humans, laboratory animals or pets. Clinical trials may have 
adverse outcomes (or harms) including side effects of the novel potential therapeutic agent, and 
failure of the novel compound to perform as well as the current standard treatment. Similarly, the 
use of placebo in trials will at worst deny, and at best delay the recipients’ access to effective 
therapy.  Clearly, there is significant potential for animals enrolled in a clinical trial to suffer more 
than they would have if they had undergone the standard treatment. 
 
Projects that involve a risk of harm to the participants need to have sound ethical and regulatory 
oversight. In fact, the existing mechanisms of approving the use of animals in scientific research 
are well suited to regulating the use of companion animals in clinical trials, consisting, as they do, 
of an initial weighing of any potential harms to the animals against the anticipated scientific 
benefits of the research. In Europe and elsewhere, if the benefits are judged to outweigh the harms 
the project is allowed to proceed and is followed by ongoing and independent oversight of the 
research) to ensure that harms are minimised and benefits maximised, and ends with a 
retrospective assessment of the actual harms and benefits. These processes have established 
important safeguards for the welfare of animals used in research, and are of vital importance since 
animal subjects of clinical trials cannot give their informed consent to participate. 
 
There is one other crucial difference between a veterinary and human clinical trial. In all 
veterinary trials, a decision can be taken to euthanase an animal. This intervention is not just an 
option, but a legal and moral obligation when suffering becomes excessive. In regulated animal 
research, it is usual to set an endpoint before the research begins: a level of suffering that cannot 
be exceeded. If this point is reached, the animal is humanely killed to end its suffering. Euthanasia 
offers crucial protection for the welfare of all animals used in research. If the subjects of research 
are people’s pets rather than laboratory animals, it is far harder to set an immutable endpoint. In 
this case, the ultimate decision on the fate of the animal does not rest with objective observers 
who have a legal responsibility to minimise suffering. It rests instead with the owner and with the 
veterinary surgeon, who is acting under the direction of the owner (and may also have a vested 
interest in the clinical trial). The potential for conflicts of interest is clear. Regulation is critical to 
ensure that animals do not have their suffering prolonged while their owners wait, potentially in 
vain, for an unproven treatment to save their dying pet. 
 
Whilst undoubtedly adding some regulatory burden, appropriate control of veterinary clinical 
trials, like all other research on animals, is essential both to ensure animal welfare and also to 
ensure that research is of high quality.  
 
For research funders, a primary criterion for supporting research that involves animals is that the 
research has been subject to appropriate ethical review and regulatory oversight. Most funders 
would not wish to support any work that might cause harm to animals if it had evaded such 
oversight by dint of a semantic distinction between ‘experiments’ and ‘clinical trials.’ A clinical 
trial is an experiment to test whether a particular treatment is efficacious. Therefore, a clinical trial 
should be regulated as such.  
 
We do not argue that trials on pets cannot yield promising scientific data, but rather seek to ensure 
that that they are not undertaken without the same objective consideration of harms and benefits 
that all other experiments on animals undergo. The regulations in the United Kingdom aim to 
protect the companion animal from the competing interests of the stakeholders in each clinical 
case, to protect the welfare of the animal, and to ensure that any suffering is minimised without 
unduly impeding scientific progress. The welfare of companion animals deserves the same degree 
of protection as the welfare of animals bred explicitly for research.  
 
 
 
Dr Huw Golledge, Universities Federation for Animal Welfare, The Old School, Brewhouse Hill, 
Wheathampstead, Hertfordshire, AL4 8AN, UK 
 
 
 Prof Paul Flecknell, Newcastle University, Newcastle upon Tyne NE1 7RU 
 
 
 
 
 
  
Dr Polly Taylor, Taylor Monroe, Gravel Head Farm, Little Downham, Nr Ely, Cambs CB6 2TY 
 
 
 
 
 
 
Prof Eddie Clutton, Wellcome Trust Critical Care Laboratory for Large Animals, Roslin Institute, 
Easter Bush, Midlothian EH25 9RG 
 
 
 
 
 
 
Dr Kathy Murphy, Comparative Biology Centre, Newcastle University, NE2 4HH 
 
 
 
 
 
 
Guen Bradbury, Innovia Technology, St Andrew’s House, St Andrew’s Road, Cambridge, CB4 
1DL 
 
  
 David Chennells, Court Farm, Olney, MK46 5EH 
 
 
Dr Gabrielle C Musk, Animal Care Services, The University of Western Australia, M720, Perth WA 
6009 Australia  
 
 
 
 
Juliet Duncan, Royal (Dick) School of Veterinary Studies, Easter Bush Campus, University of 
Edinburgh, EH25 9RG 
 
 
 
Dr Dorothy McKeegan, Institute of Biodiversity, Animal Health and Comparative Medicine, 
University of Glasgow 
 
 
Bryony Few, Charles River Laboratories, Tranent, East Lothian, EH33 2NE 
 
 
Dr Ngaire Dennison, Biological Services, University of Dundee, MSI/WTB/JBC Complex, 
Dow Street, Dundee DD1 5EH 
 
  
References 
 
EDITORIAL (2016) Pet projects need a helping hand.  Nature 540, 169. 
 
JARVIS, S.  (2010) Where do you draw the line on treatment? Veterinary Record 167, 636-637 
